XML 17 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Revenue $ 0 $ 0 $ 0 $ 0
Operating expenses:        
Research and development 492 112 1,050 298
General and administrative 1,694 452 3,386 1,427
Loss from operations (2,186) (564) (4,436) (1,725)
Other (expense) income :        
Unrealized (loss)/gain on derivatives (Note 4) (183) 19 (340) 45
Sale of Eniluracil 0 40 0 40
Other gain/(loss) 1 0 (4) (12)
Interest income and other 16 3 24 6
Total other (expense)/income, net (166) 62 (320) 79
Net loss $ (2,352) $ (502) $ (4,756) $ (1,646)
Basic net loss per common share $ (0.15) $ (0.04) $ 0.32 $ (0.13)
Diluted net loss per common share $ (0.15) $ (0.04) $ 0.32 $ (0.13)
Weighted-average number of common shares outstanding, basic 15,740 13,643 14,533 12,469
Weighted-average number of common shares outstanding, diluted 15,740 13,643 14,533 12,469